v3.25.2

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
REVENUE
Revenue		$ 3,971,438		$ 8,878,315
TOTAL REVENUE		3,971,438		8,878,315
OPERATING EXPENSES
Research and development	$ 22,047,254	12,504,769	$ 40,962,826	23,605,782
General and administrative	5,671,880	3,057,888	11,739,256	7,129,654
TOTAL OPERATING EXPENSES	27,719,134	15,562,657	52,702,082	30,735,436
LOSS FROM OPERATIONS	(27,719,134)	(11,591,219)	(52,702,082)	(21,857,121)
OTHER INCOME (EXPENSE)
Other income	14,991		27,476
Investment income	1,793,352	591,437	2,522,894	1,063,266
Loss on disposal of fixed assets			(150,673)
TOTAL OTHER INCOME (EXPENSE)	1,808,343	591,437	2,399,697	1,063,266
NET LOSS	(25,910,791)	(10,999,782)	(50,302,385)	(20,793,855)
OTHER COMPREHENSIVE INCOME (LOSS)
Net unrealized gain (loss) on marketable securities	(424,353)	(152,714)	360,619	(80,826)
COMPREHENSIVE LOSS	$ (26,335,144)	$ (11,152,496)	$ (49,941,766)	$ (20,874,681)
Net loss per share, basic (in dollars per share)	$ (0.57)	$ (0.35)	$ (1.1)	$ (0.66)
Net loss per share, diluted (in dollars per share)	$ (0.57)	$ (0.35)	$ (1.1)	$ (0.66)
Weighted average number of shares, basic (in shares)	45,709,071	31,841,964	45,673,075	31,598,296
Weighted average number of shares, diluted (in shares)	45,709,071	31,841,964	45,673,075	31,598,296

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(24))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(26))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-5

CAPRICOR THERAPEUTICS, INC. 10-Q